Cost-effectiveness Analysis of Duloxetine, Escitalopram Oxalate and Mirtazapine in the Treatment of De-pression
- VernacularTitle:度洛西汀、草酸艾司西酞普兰、米氮平治疗抑郁症的成本-效果分析
- Author:
Canchun OU
;
Xiaoxi ZHU
;
Jinfang ZHU
- Publication Type:Journal Article
- Keywords:
Depression;
Duloxetine;
Escitalopram oxalate;
Mirtazapine;
Cost-effectiveness analysis;
Pharmacoeconomics
- From:
China Pharmacist
2015;(3):449-451
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the cost-effectiveness of duloxetine, escitalopram oxalate and mirtazapine in the treatment of depression. Methods:Totally 120 cases of patients were randomly divided into three group. Group A was given duloxetine 40mg twice a day, group B was with escitalopram oxalate at the initial dose of 10mg per day, and up to 20mg per day in 2 weeks, and group C was treated with mirtazapine 30mg per day. The treatment course was eight weeks. At the 1st, 2nd, 3rd, 4th and 8th weekends after the treatment, Hamilton depression scale ( HAMD) was used to evaluate the total effective rate, and treatment emergent symptom scale ( TESS) was applied to assess the adverse drug reactions. Results:The total effective rate of group A, B and C was 87. 5%,90% and 92. 5% with the cost of 23 822. 22 yuan,33 866. 02 yuan and 19 586. 62 yuan, respectively. The cost-effectiveness ratio respectively was 27 225, 37 629 and 21 175. The incidence of adverse reactions respectively was 30%, 30% and 17. 5%. Conclusion:The cost-effectiveness of mirtazapine is the lowest in the treatment of depression, which can be considered as the best treatment regimen.
